Urogranoic acid
Brand names,
Urogranoic acid
Analogs
Urogranoic acid
Brand Names Mixture
Urogranoic acid
Chemical_Formula
C9H15N5O3
Urogranoic acid
RX_link
No information avaliable
Urogranoic acid
fda sheet
Urogranoic acid
msds (material safety sheet)
Urogranoic acid
Synthesis Reference
No information avaliable
Urogranoic acid
Molecular Weight
241.247 g/mol
Urogranoic acid
Melting Point
250-255 oC (hydrochloride salt)
Urogranoic acid
H2O Solubility
>20 mg/mL (dichloride salt)
Urogranoic acid
State
Solid
Urogranoic acid
LogP
-1.783
Urogranoic acid
Dosage Forms
No information avaliable
Urogranoic acid
Indication
For the treatment of tetrahydrobiopterin (BH4) deficiency.
Urogranoic acid
Pharmacology
Tetrahydrobiopterin (BH4) is used to convert several amino acids, including phenylalanine, to other essential molecules in the body including neurotransmitters. Tetrahydrobiopterin deficiency can be caused by mutations in GTP cyclohydrolase 1 (GCH1), 6-pyruvoyl-tetrahydropterin synthase/dimerization cofactor of hepatocyte nuclear factor 1 alpha (PCBD1), 6-pyruvoyltetrahydropterin synthase (PTS), and quinoid dihydropteridine reductase (QDPR) genes. These genes make the enzymes that are critical for producing and recycling tetrahydrobiopterin. If one of the enzymes fails to function correctly because of a gene mutation, little or no tetrahydrobiopterin is produced. As a result, phenylalanine from the diet builds up in the bloodstream and other tissues and can damage nerve cells in the brain. High levels of phenylalanine can result in signs and symptoms ranging from temporary low muscle tone to mental retardation, movement disorders, difficulty swallowing, seizures, behavioral problems, progressive problems with development, and an inability to control body temperature.
Urogranoic acid
Absorption
No information avaliable
Urogranoic acid
side effects and Toxicity
No information avaliable
Urogranoic acid
Patient Information
No information avaliable
Urogranoic acid
Organisms Affected
Humans and other mammals